Article Text

Download PDFPDF

A6.8 Biological Therapies in Juvenile Idiopathic Arthritis
  1. ML Velloso Feijoo,
  2. R Martinez Perez,
  3. J Uceda Montañes,
  4. JL Marenco de la Fuente
  1. Rheumatology Unit, Valme University Hospital, Seville, Spain


Background Biological therapies have dramatically changed the prognosis for children with juvenile idiopathic arthritis (JIA). There are doubts about the possibility of discontinuing treatment once remission is achieved. We focus in this question in our series.

Objective To assess the efficacy and safety of these drugs in our series of patients with JIA.

Matherials and Methods We identified 9 children with JIA treated with biologic therapies, and we made a description of our experience.

Results The mean age was 14.55 ± 5.85, with a female predominance (66.7%). At diagnosis, mean age was 4.94 ± 2.9, and at the beginning of biological treatment of 8.77 ± 2.63. The median time from diagnosis to initiation of biological therapy was 3.94 ± 2.83 years. The disease characteristics are detailed in the table.

Abstract A6.8 Table 1

All the children had previously received DMARDs (66.6% methotrexate (MTX) and 33.3% MTX and sulfasalazine). Eight of the 9 patients (88.9%) were taking corticosteroids at baseline. Eight received etanercept (ETN) and one Adalimumab (ADA), with good outcomes in all the patients unless 1 that had to switch from ETN to ADA due to inefficacy, and improved after the change. The steroids were suspended in 75% of children (6). Differences between mean values of CRP, ESR, and platelets from baseline to actual moment were statistically significant.

The median biologic time is 4 (1.11) years.

Actually all the children are in remission, two of them (patients 1 and 4) without biological treatment or classic DMARDs (since 5 and 2 years respectively).

None of the children have had significant adverse effects nor required hospitalisation from the beginning of therapy.

Discussion ETN has proved its efficacy in JIA (regardless of the type of onset), as it has been reported in multiple efficacy and safety studies, including long term studies of up to eight years of continuous therapy. [1, 2]

We present our experience in children treated with up to 11 years, with good outcomes in terms of efficacy and safety in all the patients, and also 2 patients still in remission after 2 and 5 years without treatment.


  1. EH Giannini et al, Long-Term Safety and Effectiveness of Etanercept in Children with juvenile idiopathic selected categories of arthritis. Arthritis Rheum. 2009, 60(9):2794–2804.

  2. Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F. A follow-up study of juvenile idiopathic arthritis Patients with etanercept discontinued due to Who disease remission. Clin Exp Rheumatol. 2010 Nov–Dec, 28(6):919–22. Epub 2011 Jan 4.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.